Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 563

The DOI matches its Crossref record; 417 of the 417 references it cites were found in a registry or an index.

Drug allergy: A 2022 practice parameter update

Open access
Khan, David A., Banerji, Aleena, Blumenthal, Kimberly G., Phillips, Elizabeth J., Solensky, Roland, White, Andrew A., Bernstein, Jonathan A., Chu, Derek K., Ellis, Anne K., Golden, David B.K., Greenhawt, Matthew J., Horner, Caroline C., Ledford, Dennis, Lieberman, Jay A., Oppenheimer, John, Rank, Matthew A., Shaker, Marcus S., Stukus, David R., Wallace, Dana, Wang, Julie, Khan, David A., Golden, David B.K., Shaker, Marcus, Stukus, David R., Khan, David A., Banerji, Aleena, Blumenthal, Kimberly G., Phillips, Elizabeth J., Solensky, Roland, White, Andrew A., Bernstein, Jonathan A., Chu, Derek K., Ellis, Anne K., Golden, David B.K., Greenhawt, Matthew J., Horner, Caroline C., Ledford, Dennis, Lieberman, Jay A., Oppenheimer, John, Rank, Matthew A., Shaker, Marcus S., Stukus, David R., Wallace, Dana, Wang, Julie·2022·Journal of Allergy and Clinical Immunology

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jaci.2022.08.028

Cites

417 of 417 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 417 references

Research works printed but not linked: 176

  1. Khan, 2012, Cutaneous drug reactions, J Allergy Clin Immunol, 130, 1225, 10.1016/j.jaci.2012.08.007 · doi:10.1016/j.jaci.2012.08.007
  2. Barbaud, 2020, Intradermal tests with drugs: an approach to standardization, Front Med, 7, 156, 10.3389/fmed.2020.00156 · doi:10.3389/fmed.2020.00156
  3. Blumenthal, 2018, Risk of meticillin resistant Staphylococcus aureus and Clostridium difficile in patients with a documented penicillin allergy: population based matched cohort study, BMJ, 361
  4. Blumenthal, 2019, Recorded penicillin allergy and risk of mortality: a population-based matched cohort study, J Gen Intern Med, 34, 1685, 10.1007/s11606-019-04991-y · doi:10.1007/s11606-019-04991-y
  5. García Rodríguez, 2019, Provocation tests in nonimmediate hypersensitivity reactions to β-lactam antibiotics in children: are extended challenges needed?, J Allergy Clin Immunol Pract, 7, 265, 10.1016/j.jaip.2018.06.023 · doi:10.1016/j.jaip.2018.06.023
  6. Gallardo, 2020, Sensitization phenotypes in immediate reactions to piperacillin-tazobactam, J Allergy Clin Immunol Pract, 8, 3175, 10.1016/j.jaip.2020.04.008 · doi:10.1016/j.jaip.2020.04.008
  7. Doña, 2020, Clinical characterization and diagnostic approaches for patients reporting hypersensitivity reactions to quinolones, J Allergy Clin Immunol Pract, 8, 2707, 10.1016/j.jaip.2020.04.051 · doi:10.1016/j.jaip.2020.04.051
  8. Cavkaytar, 2016, Testing for clarithromycin hypersensitivity: a diagnostic challenge in childhood, J Allergy Clin Immunol Pract, 4, 10.1016/j.jaip.2015.09.015 · doi:10.1016/j.jaip.2015.09.015
  9. Sala-Cunill, 2021, One-dilution rapid desensitization protocol to chemotherapeutic and biological agents: a five-year experience, J Allergy Clin Immunol Pract, 9, 4045, 10.1016/j.jaip.2021.06.024 · doi:10.1016/j.jaip.2021.06.024
  10. Weiss, 1992, Hypersensitivity reactions, Semin Oncol, 19, 458
  11. Trudeau, 1996, Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group, J Clin Oncol, 14, 422, 10.1200/JCO.1996.14.2.422 · doi:10.1200/jco.1996.14.2.422
  12. Sánchez-López, 2015, Successful oral desensitization in a patient with hypersensitivity reaction to crizotinib, J Investig Allergol Clin Immunol, 25, 307
  13. Madrigal-Burgaleta, 2019, A large single-hospital experience using drug provocation testing and rapid drug desensitization in hypersensitivity to antineoplastic and biological agents, J Allergy Clin Immunol Pract, 7, 618, 10.1016/j.jaip.2018.07.031 · doi:10.1016/j.jaip.2018.07.031
  14. Lehloenya, 2011, Outcomes of reintroducing anti-tuberculosis drugs following cutaneous adverse drug reactions, Int J Tuberc Lung Dis, 15, 1649, 10.5588/ijtld.10.0698 · doi:10.5588/ijtld.10.0698
  15. Karmacharya, 2015, Rituximab-induced serum sickness: a systematic review, Semin Arthritis Rheum, 45, 334, 10.1016/j.semarthrit.2015.06.014 · doi:10.1016/j.semarthrit.2015.06.014
  16. Foong, 2016, Lack of uniformity in the investigation and management of suspected beta-lactam allergy in children, Pediatr Allergy Immunol, 27, 527, 10.1111/pai.12557 · doi:10.1111/pai.12557
  17. Picard, 2014, A new humanized in vitro model of IgE-mediated rapid desensitization, Clin Transl Allergy, 4, O10, 10.1186/2045-7022-4-S3-O10 · doi:10.1186/2045-7022-4-s3-o10
  18. Chiriac, 2017, Optimal step doses for drug provocation tests to prove beta-lactam hypersensitivity, Allergy, 72, 552, 10.1111/all.13037 · doi:10.1111/all.13037
  19. Ozturk, 2013, Determining safe alternatives for multidrug hypersensitive patients with the alternative triple antibiotic-analgesic test, Allergol Immunopathol (Madr), 41, 189, 10.1016/j.aller.2012.01.007 · doi:10.1016/j.aller.2012.01.007
  20. Guvenir, 2016, Proven non-beta-lactam antibiotic allergy in children, Int Arch Allergy Immunol, 169, 45, 10.1159/000443830 · doi:10.1159/000443830
  21. Zambonino, 2014, Diagnostic evaluation of hypersensitivity reactions to beta-lactam antibiotics in a large population of children, Pediatr Allergy Immunol, 25, 80, 10.1111/pai.12155 · doi:10.1111/pai.12155
  22. Vezir, 2014, The evaluation of drug provocation tests in pediatric allergy clinic: a single center experience, Allergy Asthma Proc, 35, 156, 10.2500/aap.2014.35.3744 · doi:10.2500/aap.2014.35.3744
  23. Indradat, 2016, Provocation proven drug allergy in Thai children with adverse drug reactions, Asian Pac J Allergy Immunol, 34, 59
  24. Sompornrattanaphan, 2020, Fatal anaphylaxis from a second amoxicillin/clavulanic acid provocation after a prior negative provocation, J Allergy Clin Immunol Pract, 8, 752, 10.1016/j.jaip.2019.07.022 · doi:10.1016/j.jaip.2019.07.022
  25. Putterman, 1990, "Treating through" hypersensitivity to co-trimoxazole in AIDS patients, Lancet, 336, 52, 10.1016/0140-6736(90)91563-P · doi:10.1016/0140-6736(90)91563-p
  26. Trautmann, 2017, "Treating through" decision and follow-up in antibiotic therapy-associated exanthemas, J Allergy Clin Immunol Pract, 5, 1650, 10.1016/j.jaip.2017.03.032 · doi:10.1016/j.jaip.2017.03.032
  27. Trubiano, 2021, Treating through drug-associated exanthems in drug allergy management: current evidence and clinical aspects, J Allergy Clin Immunol Pract, 9, 2984, 10.1016/j.jaip.2021.04.008 · doi:10.1016/j.jaip.2021.04.008
  28. Lehloenya, 2015, Lack of cross-toxicity between isoniazid and ethionamide in severe cutaneous adverse drug reactions: a series of 25 consecutive confirmed cases, J Antimicrob Chemother, 70, 2648, 10.1093/jac/dkv158 · doi:10.1093/jac/dkv158
  29. Garcia-Neuer, 2018, Drug-induced paradoxical vocal fold motion, J Allergy Clin Immunol Pract, 6, 90, 10.1016/j.jaip.2017.08.020 · doi:10.1016/j.jaip.2017.08.020
  30. Raley, 2020, Drug-associated inducible laryngeal obstruction complicating penicillin allergy testing, Ann Allergy Asthma Immunol, 125, 599, 10.1016/j.anai.2020.06.031 · doi:10.1016/j.anai.2020.06.031
  31. Phillips, 2019, Controversies in drug allergy: testing for delayed reactions, J Allergy Clin Immunol, 143, 66, 10.1016/j.jaci.2018.10.030 · doi:10.1016/j.jaci.2018.10.030
  32. Barbaud, 2014, Skin testing and patch testing in non-IgE-mediated drug allergy, Curr Allergy Asthma Rep, 14, 442, 10.1007/s11882-014-0442-8 · doi:10.1007/s11882-014-0442-8
  33. Alvarez-Arango, 2021, Vancomycin immediate skin responses in vancomycin-naïve subjects, Clin Exp Allergy, 51, 932, 10.1111/cea.13850 · doi:10.1111/cea.13850
  34. Klaewsongkram, 2019, Analysis of HLA-B allelic variation and IFN-gamma ELISpot responses in patients with severe cutaneous adverse reactions associated with drugs, J Allergy Clin Immunol Pract, 7, 219, 10.1016/j.jaip.2018.05.004 · doi:10.1016/j.jaip.2018.05.004
  35. Suthumchai, 2018, The measurement of drug-induced interferon gamma-releasing cells and lymphocyte proliferation in severe cutaneous adverse reactions, J Eur Acad Dermatol Venereol, 32, 992, 10.1111/jdv.14890 · doi:10.1111/jdv.14890
  36. Trubiano, 2017, Drug-specific upregulation of CD137 on CD8+ T cells aids in the diagnosis of multiple antibiotic toxic epidermal necrolysis, J Allergy Clin Immunol Pract, 5, 823, 10.1016/j.jaip.2016.09.043 · doi:10.1016/j.jaip.2016.09.043
  37. Fernandez, 2015, Genome-wide analysis links NFATC2 with asparaginase hypersensitivity, Blood, 126, 69, 10.1182/blood-2015-02-628800 · doi:10.1182/blood-2015-02-628800
  38. Khan, 2020, Pharmacogenomic biomarkers in allergy and immunology practice, J Allergy Clin Immunol, 146, 509, 10.1016/j.jaci.2020.05.050 · doi:10.1016/j.jaci.2020.05.050
  39. Macy, 2011, Reply. J Allergy Clin Immunol, 128, 686, 10.1016/j.jaci.2011.04.055 · doi:10.1016/j.jaci.2011.04.055
  40. Levine, 1967, Prediction of penicillin allergy by immunological tests, Ann N Y Acad Sci, 145, 298, 10.1111/j.1749-6632.1967.tb50227.x · doi:10.1111/j.1749-6632.1967.tb50227.x
  41. Ibia, 2000, Antibiotic rashes in children: a survey in a private practice setting, Arch Dermatol, 136, 849, 10.1001/archderm.136.7.849 · doi:10.1001/archderm.136.7.849
  42. Kerns, 1973, Ampicillin rash in children: relationship to penicillin allergy and infectious mononucleosis, Am J Dis Child, 125, 187, 10.1001/archpedi.1973.04160020023004 · doi:10.1001/archpedi.1973.04160020023004
  43. Patel, 1967, Skin rash with infectious mononucleosis and ampicillin, Pediatrics, 40, 910, 10.1542/peds.40.5.910 · doi:10.1542/peds.40.5.910
  44. Zhang, 2019, Drug-induced severe cutaneous adverse reactions: determine the cause and prevention, Ann Allergy Asthma Immunol, 123, 483, 10.1016/j.anai.2019.08.004 · doi:10.1016/j.anai.2019.08.004
  45. Marcos Bravo, 1995, Hypersensitivity to cefuroxime with good tolerance to other betalactams, Allergy, 50, 359, 10.1111/j.1398-9995.1995.tb01160.x · doi:10.1111/j.1398-9995.1995.tb01160.x
  46. Poston, 2004, Cefazolin tolerance does not predict ceftriaxone hypersensitivity: unique side chains precipitate anaphylaxis, Pharmacotherapy, 24, 668, 10.1592/phco.24.6.668.34753 · doi:10.1592/phco.24.6.668.34753
  47. Testi, 2010, Nonirritating concentration for skin testing with cephalosporins, J Investig Allergol Clin Immunol, 20, 171
  48. Koo, 2022, Retrospective stratification of cephalosporin allergy label risk using validated penicillin allergy frameworks, J Allergy Clin Immunol Pract, 10, 2472, 10.1016/j.jaip.2022.05.032 · doi:10.1016/j.jaip.2022.05.032
  49. Pedersen-Bjergaard, 1967, Cephalothin in the treatment of penicillin sensitive patients, Acta Allergol, 22, 299, 10.1111/j.1398-9995.1967.tb03226.x · doi:10.1111/j.1398-9995.1967.tb03226.x
  50. Shepherd, 1993, Administration of cephalosporin antibiotics to patients with a history of penicillin allergy, J Allergy Clin Immunol Pract, 91, 262
  51. Chiron, 2020, Allergy to third- and second-generation cephalosporins in confirmed penicillin-allergic patients, J Allergy Clin Immunol Pract, 8, 2409, 10.1016/j.jaip.2020.03.021 · doi:10.1016/j.jaip.2020.03.021
  52. Li, 2019, Cross-reactivity to penicillins in cephalosporin anaphylaxis, Br J Anaesth, 123, e532, 10.1016/j.bja.2019.09.011 · doi:10.1016/j.bja.2019.09.011
  53. Sodhi, 2004, Is it safe to use carbapenems in patients with a history of allergy to penicillin?, J Antimicrob Chemother, 54, 1155, 10.1093/jac/dkh454 · doi:10.1093/jac/dkh454
  54. Prescott, 2004, Incidence of carbapenem-associated allergic-type reactions among patients with versus patients without a reported penicillin allergy, Clin Infect Dis, 38, 1102, 10.1086/382880 · doi:10.1086/382880
  55. McConnell, 2000, Incidence of imipenem hypersensitivity reactions in febrile neutropenic bone marrow transplant patients with a history of penicillin allergy, Clin Infect Dis, 31, 1512, 10.1086/317507 · doi:10.1086/317507
  56. Sanchez-Borges, 2001, Tolerability to new COX-2 inhibitors in NSAID-sensitive patients with cutaneous reactions, Ann Allergy Asthma Immunol, 87, 201, 10.1016/S1081-1206(10)62226-0 · doi:10.1016/s1081-1206(10)62226-0
  57. Kula, 2014, A systematic review: can one prescribe carbapenems to patients with IgE-mediated allergy to penicillins or cephalosporins?, Clin Infect Dis, 59, 1113, 10.1093/cid/ciu587 · doi:10.1093/cid/ciu587
  58. Adkinson, 1990, Immunogenicity and cross-allergenicity of aztreonam, Am J Med, 88, S3
  59. Saxon, 1985, Investigation into the immunologic cross-reactivity of aztreonam with other beta-lactam antibiotics, Am J Med, 78, 19, 10.1016/0002-9343(85)90198-6 · doi:10.1016/0002-9343(85)90198-6
  60. Graninger, 1985, Aztreonam efficacy in difficult-to-treat infections and tolerance in patients with beta-lactam hypersensitivity, Chemioterapia, 4, 64
  61. Adkinson, 1984, Immunology of the monobactam aztreonam, Antimicrob Agents Chemother, 25, 93, 10.1128/AAC.25.1.93 · doi:10.1128/aac.25.1.93
  62. Adkinson, 1985, Cross-allergenicity and immunogenicity of aztreonam, Rev Infect Dis, 7, S613, 10.1093/clinids/7.Supplement_4.S613 · doi:10.1093/clinids/7.supplement_4.s613
  63. Vaisman, 2017, Clarifying a "penicillin" allergy: a teachable moment, JAMA Intern Med, 177, 269, 10.1001/jamainternmed.2016.8185 · doi:10.1001/jamainternmed.2016.8185
  64. Belchi-Hernandez, 1996, Management of adverse reactions to prophylactic trimethoprim-sulfamethoxazole in patients with human immunodeficiency virus infection, Ann Allergy Asthma Immunol, 76, 355, 10.1016/S1081-1206(10)60037-3 · doi:10.1016/s1081-1206(10)60037-3
  65. Ozkaya-Bayazit, 1999, Topical provocation in 27 cases of cotrimoxazole-induced fixed drug eruption, Contact Dermatitis, 41, 185, 10.1111/j.1600-0536.1999.tb06127.x · doi:10.1111/j.1600-0536.1999.tb06127.x
  66. Bonfanti, 2000, The effectiveness of desensitization versus rechallenge treatment in HIV-positive patients with previous hypersensitivity to TMP-SMX: a randomized multicentric study. CISAI Group, Biomed Pharmacother, 54, 45, 10.1016/S0753-3322(00)88640-0 · doi:10.1016/s0753-3322(00)88640-0
  67. Straatmann, 2002, A randomized, pilot trial comparing full versus escalating dose regimens for the desensitization of AIDS patients allergic to sulfonamides, Braz J Infect Dis, 6, 276, 10.1590/S1413-86702002000600002 · doi:10.1590/s1413-86702002000600002
  68. Leoung, 2001, Trimethoprim-sulfamethoxazole (TMP-SMZ) dose escalation versus direct rechallenge for Pneumocystis Carinii pneumonia prophylaxis in human immunodeficiency virus-infected patients with previous adverse reaction to TMP-SMZ, J Infect Dis, 184, 992, 10.1086/323353 · doi:10.1086/323353
  69. Gluckstein, 1995, Rapid oral desensitization to trimethoprim-sulfamethoxazole (TMP-SMZ): use in prophylaxis for Pneumocystis carinii pneumonia in patients with AIDS who were previously intolerant to TMP-SMZ, Clin Infect Dis, 20, 849, 10.1093/clinids/20.4.849 · doi:10.1093/clinids/20.4.849
  70. Hughes, 1986, Co-trimoxazole desensitization in bone marrow transplantation, Ann Intern Med, 105, 148, 10.7326/0003-4819-105-1-148 · doi:10.7326/0003-4819-105-1-148
  71. Soffritti, 2003, Successful desensitization to trimethoprim-sulfamethoxazole after allogeneic haematopoietic stem cell transplantation: preliminary observations, Med Pediatr Oncol, 40, 271, 10.1002/mpo.10196 · doi:10.1002/mpo.10196
  72. Krantz, 2021, Reply to “The safety and efficacy of direct oral challenge in trimethoprim-sulfamethoxazole antibiotic allergy”, J Allergy Clin Immunol Pract, 9, 3849, 10.1016/j.jaip.2021.07.027 · doi:10.1016/j.jaip.2021.07.027
  73. Ball, 2004, A new respiratory fluoroquinolone, oral gemifloxacin: a safety profile in context, Int J Antimicrob Agents, 23, 421, 10.1016/j.ijantimicag.2004.02.014 · doi:10.1016/j.ijantimicag.2004.02.014
  74. Manfredi, 2004, Detection of specific IgE to quinolones, J Allergy Clin Immunol, 113, 155, 10.1016/j.jaci.2003.09.035 · doi:10.1016/j.jaci.2003.09.035
  75. Venturini Diaz, 2017, In vivo diagnostic tests in adverse reactions to quinolones, J Investig Allergol Clin Immunol, 17, 393
  76. Anovadiya, 2011, Cross sensitivity between ciprofloxacin and levofloxacin for an immediate hypersensitivity reaction, J Pharmacol Pharmacother, 2, 187, 10.4103/0976-500X.83285 · doi:10.4103/0976-500x.83285
  77. Davila, 1993, Cross-reactivity between quinolones: report of three cases, Allergy, 48, 388, 10.1111/j.1398-9995.1993.tb02413.x · doi:10.1111/j.1398-9995.1993.tb02413.x
  78. Gonzalez-Mancebo, 2004, Immediate hypersensitivity to levofloxacin diagnosed through skin prick test, Ann Pharmacother, 38, 354, 10.1345/aph.1D159 · doi:10.1345/aph.1d159
  79. Lobera, 2010, Allergy to quinolones: low cross-reactivity to levofloxacin, J Investig Allergol Clin Immunol, 20, 607
  80. Sanchez-Morillas, 2010, Systemic anaphylaxis caused by moxifloxacin, Allergol Immunopathol (Madr), 38, 226, 10.1016/j.aller.2009.09.008 · doi:10.1016/j.aller.2009.09.008
  81. Demir, 2017, Usefulness of in vivo and in vitro diagnostic tests in the diagnosis of hypersensitivity reactions to quinolones and in the evaluation of cross-reactivity: a comprehensive study including the latest quinolone gemifloxacin, Allergy Asthma Immunol Res, 9, 347, 10.4168/aair.2017.9.4.347 · doi:10.4168/aair.2017.9.4.347
  82. Gea-Banacloche, 1996, Ciprofloxacin desensitization, J Allergy Clin Immunol, 97, 1426, 10.1016/S0091-6749(96)70218-X · doi:10.1016/s0091-6749(96)70218-x
  83. Lantner, 1995, Ciprofloxacin desensitization in a patient with cystic fibrosis, J Allergy Clin Immunol, 96, 1001, 10.1016/S0091-6749(95)70240-7 · doi:10.1016/s0091-6749(95)70240-7
  84. Treadway, 1996, Paediatric safety of azithromycin: worldwide experience, J Antimicrob Chemother, 37, 143, 10.1093/jac/37.suppl_C.143 · doi:10.1093/jac/37.suppl_c.143
  85. van der Linden, 1998, Skin reactions to antibacterial agents in general practice, J Clin Epidemiol, 51, 703, 10.1016/S0895-4356(98)00041-9 · doi:10.1016/s0895-4356(98)00041-9
  86. Benahmed, 2004, The accuracy of the diagnosis of suspected macrolide antibiotic hypersensitivity: results of a single-blinded trial, Allergy, 59, 1130, 10.1111/j.1398-9995.2004.00638.x · doi:10.1111/j.1398-9995.2004.00638.x
  87. Lammintausta, 2005, Oral challenge in patients with suspected cutaneous adverse drug reactions: findings in 784 patients during a 25-year-period, Acta Derm Venereol, 85, 491, 10.1080/00015550510042859 · doi:10.1080/00015550510042859
  88. Mori, 2010, Sensitivity and specificity of skin tests in the diagnosis of clarithromycin allergy, Ann Allergy Asthma Immunol, 104, 417, 10.1016/j.anai.2010.03.010 · doi:10.1016/j.anai.2010.03.010
  89. Laurie, 2000, Successful clarithromycin desensitization in a macrolide-sensitive patient (abstract), Ann Allergy Asthma Immunol, 84, 116
  90. Asero, 2005, Oral aspirin challenges in patients with a history of intolerance to single non-steroidal anti-inflammatory drugs, Clin Exp Allergy, 35, 713, 10.1111/j.1365-2222.2005.2228.x · doi:10.1111/j.1365-2222.2005.2228.x
  91. Asero, 2006, Use of ketoprofen oral challenges to detect cross-reactors among patients with a history of aspirin-induced urticaria, Ann Allergy Asthma Immunol, 97, 187, 10.1016/S1081-1206(10)60011-7 · doi:10.1016/s1081-1206(10)60011-7
  92. Kim, 2007, The prevalence of Samter's triad in patients undergoing functional endoscopic sinus surgery, Ear Nose Throat J, 86, 396, 10.1177/014556130708600715 · doi:10.1177/014556130708600715
  93. Dursun, 2008, Predicting outcomes of oral aspirin challenges in patients with asthma, nasal polyps, and chronic sinusitis, Ann Allergy Asthma Immunol, 100, 420, 10.1016/S1081-1206(10)60465-6 · doi:10.1016/s1081-1206(10)60465-6
  94. Cook, 2017, Use of a composite symptom score during challenge in patients with suspected aspirin-exacerbated respiratory disease, Ann Allergy Asthma Immunol, 118, 597, 10.1016/j.anai.2017.02.016 · doi:10.1016/j.anai.2017.02.016
  95. Staso, 2021, Scoring tool for systemic symptoms during aspirin challenge detects mediator production in aspirin-exacerbated respiratory disease, Ann Allergy Asthma Immunol, 127, 131, 10.1016/j.anai.2021.03.025 · doi:10.1016/j.anai.2021.03.025
  96. White, 2013, The clinical dilemma of "silent desensitization" in aspirin-exacerbated respiratory disease, Allergy Asthma Proc, 34, 378, 10.2500/aap.2013.34.3670 · doi:10.2500/aap.2013.34.3670
  97. Lang, 2018, Omalizumab can inhibit respiratory reaction during aspirin desensitization, Ann Allergy Asthma Immunol, 121, 98, 10.1016/j.anai.2018.05.007 · doi:10.1016/j.anai.2018.05.007
  98. Huang, 2019, Sinus surgery improves lower respiratory tract reactivity during aspirin desensitization for AERD, J Allergy Clin Immunol Pract, 7, 1647, 10.1016/j.jaip.2019.02.037 · doi:10.1016/j.jaip.2019.02.037
  99. Chen, 2015, An hourly dose-escalation desensitization protocol for aspirin-exacerbated respiratory disease, J Allergy Clin Immunol Pract, 3, 926, 10.1016/j.jaip.2015.06.013 · doi:10.1016/j.jaip.2015.06.013
  100. Lee, 2010, Use of intranasal ketorolac and modified oral aspirin challenge for desensitization of aspirin-exacerbated respiratory disease, Ann Allergy Asthma Immunol, 105, 130, 10.1016/j.anai.2010.05.020 · doi:10.1016/j.anai.2010.05.020
  101. DeGregorio, 2019, A 1-day, 90-minute aspirin challenge and desensitization protocol in aspirin-exacerbated respiratory disease, J Allergy Clin Immunol Pract, 7, 1174, 10.1016/j.jaip.2018.10.032 · doi:10.1016/j.jaip.2018.10.032
  102. Pelletier, 2019, Comparable safety of 2 aspirin desensitization protocols for aspirin exacerbated respiratory disease, J Allergy Clin Immunol Pract, 7, 1319, 10.1016/j.jaip.2018.08.004 · doi:10.1016/j.jaip.2018.08.004
  103. Pleskow, 1982, Aspirin desensitization in aspirin-sensitive asthmatic patients: clinical manifestations and characterization of the refractory period, J Allergy Clin Immunol, 69, 11, 10.1016/0091-6749(82)90081-1 · doi:10.1016/0091-6749(82)90081-1
  104. Wangberg, 2021, Perioperative management and perceived risks of sinus surgery in patients with aspirin-exacerbated respiratory disease, Int Forum Allergy Rhinol, 11, 1132, 10.1002/alr.22789 · doi:10.1002/alr.22789
  105. Do, 2019, Long-term assessment of aspirin desensitization shows successful bridging with non-aspirin nonsteroidal anti-inflammatory drugs for procedures, Allergy Asthma Proc, 40, 311, 10.2500/aap.2019.40.4239 · doi:10.2500/aap.2019.40.4239
  106. White, 2005, The blocking effect of essential controller medications during aspirin challenges in patients with aspirin-exacerbated respiratory disease, Ann Allergy Asthma Immunol, 95, 330, 10.1016/S1081-1206(10)61150-7 · doi:10.1016/s1081-1206(10)61150-7
  107. White, 2006, Effect of leukotriene modifier drugs on the safety of oral aspirin challenges, Ann Allergy Asthma Immunol, 97, 688, 10.1016/S1081-1206(10)61101-5 · doi:10.1016/s1081-1206(10)61101-5
  108. Kowalski, 1986, Clinical efficacy of aspirin in "desensitised" aspirin-sensitive asthmatics, Eur J Respir Dis, 69, 219
  109. Cho, 2014, Long-term sinonasal outcomes of aspirin desensitization in aspirin exacerbated respiratory disease, Otolaryngol Head Neck Surg, 151, 575, 10.1177/0194599814545750 · doi:10.1177/0194599814545750
  110. Sánchez-Borges, 2015, Aspirin-exacerbated cutaneous disease (AECD) is a distinct subphenotype of chronic spontaneous urticaria, J Eur Acad Dermatol Venereol, 29, 698, 10.1111/jdv.12658 · doi:10.1111/jdv.12658
  111. Asero, 2002, Autoreactivity is highly prevalent in patients with multiple intolerances to NSAIDs, Ann Allergy Asthma Immunol, 88, 468, 10.1016/S1081-1206(10)62384-8 · doi:10.1016/s1081-1206(10)62384-8
  112. Asero, 2003, Intolerance to nonsteroidal anti-inflammatory drugs might precede by years the onset of chronic urticaria, J Allergy Clin Immunol, 111, 1095, 10.1067/mai.2003.1444 · doi:10.1067/mai.2003.1444
  113. Perrone, 2003, Tolerability of rofecoxib in patients with adverse reactions to nonsteroidal anti-inflammatory drugs: a study of 216 patients and literature review, Int Arch Allergy Immunol, 132, 82, 10.1159/000073268 · doi:10.1159/000073268
  114. Nettis, 2002, Tolerability of rofecoxib in patients with cutaneous adverse reactions to nonsteroidal anti-inflammatory drugs, Ann Allergy Asthma Immunol, 88, 331, 10.1016/S1081-1206(10)62017-0 · doi:10.1016/s1081-1206(10)62017-0
  115. Sánchez, 2020, Clinical control of CSU with antihistamines allows for tolerance of NSAID-exacerbated cutaneous disease, J Allergy Clin Immunol Pract, 8, 3577, 10.1016/j.jaip.2020.06.057 · doi:10.1016/j.jaip.2020.06.057
  116. Walters, 2016, Tolerance to nonsteroidal anti-inflammatory drugs and alcohol after omalizumab treatment in a patient with chronic urticaria, Ann Allergy Asthma Immunol, 117, 559, 10.1016/j.anai.2016.08.020 · doi:10.1016/j.anai.2016.08.020
  117. Asero, 2018, Restoration of aspirin tolerance following omalizumab treatment in a patient with chronic spontaneous urticaria, Eur Ann Allergy Clin Immunol, 50, 226, 10.23822/EurAnnACI.1764-1489.36 · doi:10.23822/eurannaci.1764-1489.36
  118. Doña, 2017, Natural evolution in patients with nonsteroidal anti-inflammatory drug-induced urticaria/angioedema, Allergy, 72, 1346, 10.1111/all.13147 · doi:10.1111/all.13147
  119. Doña, 2014, NSAID-induced urticaria/angioedema does not evolve into chronic urticaria: a 12-year follow-up study, Allergy, 69, 438, 10.1111/all.12335 · doi:10.1111/all.12335
  120. Goksel, 2010, Safety of meloxicam in patients with aspirin/non-steroidal anti-inflammatory drug-induced urticaria and angioedema, J Dermatol, 37, 973, 10.1111/j.1346-8138.2010.00948.x · doi:10.1111/j.1346-8138.2010.00948.x
  121. Rossini, 2008, Aspirin desensitization in patients undergoing percutaneous coronary interventions with stent implantation, Am J Cardiol, 101, 786, 10.1016/j.amjcard.2007.10.045 · doi:10.1016/j.amjcard.2007.10.045
  122. Silberman, 2005, Rapid desensitization procedure for patients with aspirin hypersensitivity undergoing coronary stenting, Am J Cardiol, 95, 509, 10.1016/j.amjcard.2004.10.022 · doi:10.1016/j.amjcard.2004.10.022
  123. Moore, 1980, Nonsteroidal anti-inflammatory intolerance. an anaphylactic reaction to tolmetin, Arch Intern Med, 140, 1105, 10.1001/archinte.1980.00330190117037 · doi:10.1001/archinte.1980.00330190117037
  124. Alkhawajah, 1993, Fatal anaphylactic reaction to diclofenac, Forensic Sci Int, 60, 107, 10.1016/0379-0738(93)90098-U · doi:10.1016/0379-0738(93)90098-u
  125. Himly, 2003, IgE-mediated immediate-type hypersensitivity to the pyrazolone drug propyphenazone, J Allergy Clin Immunol, 111, 882, 10.1067/mai.2003.163 · doi:10.1067/mai.2003.163
  126. Couto, 2012, IgE-mediated metamizol allergy and the usefulness of the cellular allergen stimulation test, Eur Ann Allergy Clin Immunol, 44, 113
  127. Fontaine, 2005, Anaphylactic shock caused by a selective allergy to celecoxib, with no allergy to rofecoxib or sulfamethoxazole, J Allergy Clin Immunol, 115, 633, 10.1016/j.jaci.2004.10.045 · doi:10.1016/j.jaci.2004.10.045
  128. Cortellini, 2017, Clinical approach on challenge and desensitization procedures with aspirin in patients with ischemic heart disease and nonsteroidal anti-inflammatory drug hypersensitivity, Allergy, 72, 498, 10.1111/all.13068 · doi:10.1111/all.13068
  129. Gendernalik, 2009, Fixed drug eruptions: a case report and review of the literature, Cutis, 84, 215
  130. Blanca-López, 2018, Acetyl salicylic acid challenge in children with hypersensitivity reactions to nonsteroidal anti-inflammatory drugs differentiates between cross-intolerant and selective responders, J Allergy Clin Immunol Pract, 6, 1226, 10.1016/j.jaip.2017.08.029 · doi:10.1016/j.jaip.2017.08.029
  131. Mori, 2020, A multicenter retrospective study on hypersensitivity reactions to nonsteroidal anti-inflammatory drugs (NSAIDs) in children: a report from the European Network on Drug Allergy (ENDA) Group, J Allergy Clin Immunol Pract, 8, 1022, 10.1016/j.jaip.2019.10.049 · doi:10.1016/j.jaip.2019.10.049
  132. Cousin, 2016, Phenotypical characterization of children with hypersensitivity reactions to NSAIDs, Pediatr Allergy Immunol, 27, 743, 10.1111/pai.12596 · doi:10.1111/pai.12596
  133. Camara, 2005, Clopidogrel (Plavix) desensitization: a case series, Catheter Cardiovasc Interv, 65, 525
  134. Camara, 2007, Clopidogrel (Plavix) desensitization protocol, Catheter Cardiovasc Interv, 69, 154
  135. Makrilia, 2010, Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review, Met Based Drugs, 2010, 10.1155/2010/207084 · doi:10.1155/2010/207084
  136. Shibata, 2009, Oxaliplatin-induced allergic reaction in patients with colorectal cancer in Japan, Int J Clin Oncol, 14, 397, 10.1007/s10147-009-0883-6 · doi:10.1007/s10147-009-0883-6
  137. Pellegrino, 2017, Nab-paclitaxel after docetaxel hypersensitivity reaction: case report and literature review, Acta Biomed, 88, 329
  138. Tsao, 2022, Hypersensitivity reactions to platinum agents and taxanes, Clin Rev Allergy Immunol, 62, 432, 10.1007/s12016-021-08877-y · doi:10.1007/s12016-021-08877-y
  139. Pasteur, 2019, Low cross-reactivity between cisplatin and other platinum salts, J Allergy Clin Immunol Pract, 7, 1894, 10.1016/j.jaip.2019.01.057 · doi:10.1016/j.jaip.2019.01.057
  140. Sánchez-Muñoz, 2011, Cross-sensitivity between taxanes in patients with breast cancer, Clin Transl Oncol, 13, 904, 10.1007/s12094-011-0753-3 · doi:10.1007/s12094-011-0753-3
  141. Dizon, 2006, Cross-sensitivity between paclitaxel and docetaxel in a women's cancers program, Gynecol Oncol, 100, 149, 10.1016/j.ygyno.2005.08.004 · doi:10.1016/j.ygyno.2005.08.004
  142. Koren, 2002, Hypersensitivity reaction to cisplatin during chemoradiation therapy for gynecologic malignancy, Am J Clin Oncol, 25, 625, 10.1097/00000421-200212000-00020 · doi:10.1097/00000421-200212000-00020
  143. Polyzos, 2009, Clinical features of hypersensitivity reactions to oxaliplatin: a 10-year experience, Oncology, 76, 36, 10.1159/000178163 · doi:10.1159/000178163
  144. Syrigou, 2010, Administration of cisplatin in three patients with carboplatin hypersensitivity: is skin testing useful?, Anticancer Drugs, 21, 333, 10.1097/CAD.0b013e32833418c0 · doi:10.1097/cad.0b013e32833418c0
  145. Leguy-Seguin, 2007, Diagnostic and predictive value of skin testing in platinum salt hypersensitivity, J Allergy Clin Immunol, 119, 726, 10.1016/j.jaci.2006.11.640 · doi:10.1016/j.jaci.2006.11.640
  146. Koshiba, 2009, Incidence of Carboplatin-related hypersensitivity reactions in Japanese patients with gynecologic malignancies, Int J Gynecol Cancer, 19, 460, 10.1111/IGC.0b013e3181a1bf2e · doi:10.1111/igc.0b013e3181a1bf2e
  147. Goldberg, 1996, A modified, prolonged desensitization protocol in carboplatin allergy, J Allergy Clin Immunol, 98, 841, 10.1016/S0091-6749(96)70134-3 · doi:10.1016/s0091-6749(96)70134-3
  148. Gomez, 2009, Carboplatin hypersensitivity: does introduction of skin test and desensitization reliably predict and avoid the problem? A prospective single-center study, Int J Gynecol Cancer, 19, 1284, 10.1111/IGC.0b013e3181a418ff · doi:10.1111/igc.0b013e3181a418ff
  149. Levin, 2020, Platin risk stratification algorithm with modified intradermal skin test protocol, J Allergy Clin Immunol Pract, 8, 1139, 10.1016/j.jaip.2019.08.055 · doi:10.1016/j.jaip.2019.08.055
  150. Chung, 2018, A new non-dilution rapid desensitization protocol successfully applied to all-grade platinum hypersensitivity, Cancer Chemother Pharmacol, 82, 777, 10.1007/s00280-018-3662-0 · doi:10.1007/s00280-018-3662-0
  151. Madrigal-Burgaleta, 2013, Hypersensitivity and desensitization to antineoplastic agents: outcomes of 189 procedures with a new short protocol and novel diagnostic tools assessment, Allergy, 68, 853, 10.1111/all.12105 · doi:10.1111/all.12105
  152. Alvarez-Cuesta, 2015, Delving into cornerstones of hypersensitivity to antineoplastic and biological agents: value of diagnostic tools prior to desensitization, Allergy, 70, 784, 10.1111/all.12620 · doi:10.1111/all.12620
  153. Otani, 2018, Utility of risk stratification for paclitaxel hypersensitivity reactions, J Allergy Clin Immunol Pract, 6, 1266, 10.1016/j.jaip.2017.08.025 · doi:10.1016/j.jaip.2017.08.025
  154. De Lira-Quezada, 2018, Early and delayed hypersensitivity reactions to paclitaxel: desensitization as a challenge, Ann Allergy Asthma Immunol, 121, S72, 10.1016/j.anai.2018.09.234 · doi:10.1016/j.anai.2018.09.234
  155. Horvat, 2016, The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intolerance, Leuk Res, 50, 17, 10.1016/j.leukres.2016.08.014 · doi:10.1016/j.leukres.2016.08.014
  156. August, 2020, Desensitization to pegaspargase in children with acute lymphoblastic leukemia and lymphoblastic lymphoma, Pediatr Blood Cancer, 67, 10.1002/pbc.28021 · doi:10.1002/pbc.28021
  157. Sato, 2020, Osimertinib-associated toxic epidermal necrolysis in a lung cancer patient harboring an EGFR mutation—a case report and a review of the literature, Medicina (Kaunas), 56, 403, 10.3390/medicina56080403 · doi:10.3390/medicina56080403
  158. Pasadyn, 2020, Cutaneous adverse effects of biologic medications, Cleve Clin J Med, 87, 288, 10.3949/ccjm.87a.19119 · doi:10.3949/ccjm.87a.19119
  159. Iimura, 2018, NSAIDs may prevent EGFR-TKI-related skin rash in non-small cell lung cancer patients, Int J Clin Pharmacol Ther, 56, 551, 10.5414/CP203323 · doi:10.5414/cp203323
  160. Makino, 2013, Treatment strategy for reducing the risk of rituximab-induced cytokine release syndrome in patients with intravascular large B-cell lymphoma: a case report and review of the literature, J Med Case Rep, 7, 280, 10.1186/1752-1947-7-280 · doi:10.1186/1752-1947-7-280
  161. Gold, 2017, Premedication use in preventing acute infliximab infusion reactions in patients with inflammatory bowel disease: a single center cohort study, Inflamm Bowel Dis, 23, 1882, 10.1097/MIB.0000000000001189 · doi:10.1097/mib.0000000000001189
  162. Rocchi, 2014, Hypersensitivity reactions to tocilizumab: role of skin tests in diagnosis, Rheumatology (Oxford), 53, 1527, 10.1093/rheumatology/keu181 · doi:10.1093/rheumatology/keu181
  163. Cansever, 2018, Successful slow desensitization to tocilizumab in a 15-year-old patient, J Investig Allergol Clin Immunol, 28, 436, 10.18176/jiaci.0314 · doi:10.18176/jiaci.0314
  164. Sakaue, 2014, Tocilizumab-induced leucocytoclastic vasculitis in a patient with rheumatoid arthritis, Rheumatology (Oxford), 53, 1529, 10.1093/rheumatology/keu008 · doi:10.1093/rheumatology/keu008
  165. Cortellini, 2018, Effective desensitization to tocilizumab in delayed hypersensitivity reaction, Pharmacology, 102, 114, 10.1159/000490419 · doi:10.1159/000490419
  166. Weiss, 2020, A case of serum sickness-like reaction in an adult treated with omalizumab, Mil Med, 185, e912, 10.1093/milmed/usz357 · doi:10.1093/milmed/usz357
  167. Jeimy, 2019, Dermatomyositis associated with omalizumab therapy for severe asthma: a case report, Allergy Asthma Clin Immunol, 15, 4, 10.1186/s13223-019-0319-4 · doi:10.1186/s13223-019-0319-4
  168. Brockow, 2021, "Idiopathic" anaphylaxis caused by carboxymethylcellulose in ice cream, J Allergy Clin Immunol Pract, 9, 555, 10.1016/j.jaip.2020.10.051 · doi:10.1016/j.jaip.2020.10.051
  169. Klein, 1998, Anaphylaxis from the carboxymethylcellulose component of barium sulfate suspension, N Engl J Med, 338, 623, 10.1056/NEJM199802263380915 · doi:10.1056/nejm199802263380915
  170. Ohnishi, 2019, Anaphylaxis to carboxymethylcellulose: add food additives to the list of elicitors, Pediatrics, 143, 10.1542/peds.2018-1180 · doi:10.1542/peds.2018-1180
  171. Bircher, 2004, Oral tolerance of carboxymethylcellulose in patients with anaphylaxis to parenteral carboxymethylcellulose, Ann Allergy Asthma Immunol, 92, 580, 10.1016/S1081-1206(10)61769-3 · doi:10.1016/s1081-1206(10)61769-3
  172. Garcia-Ortega, 2003, Carboxymethylcellulose allergy as a cause of suspected corticosteroid anaphylaxis, Ann Allergy Asthma Immunol, 91, 421, 10.1016/S1081-1206(10)61698-5 · doi:10.1016/s1081-1206(10)61698-5
  173. Rutkowski, 2020, Immediate hypersensitivity reactions to steroids and steroid containing medications, Curr Opin Allergy Clin Immunol, 20, 362, 10.1097/ACI.0000000000000655 · doi:10.1097/aci.0000000000000655
  174. Bonanni, 2021, Anaphylaxis after injecting a hemostatic agent containing gelatin into vertebral bone under pressure-a warning, Spine Deform, 9, 1191, 10.1007/s43390-020-00273-4 · doi:10.1007/s43390-020-00273-4
  175. Aminsharifi, 2019, Major complications and adverse events related to the injection of the SpaceOAR hydrogel system before radiotherapy for prostate cancer: review of the manufacturer and user facility device experience database, J Endourol, 33, 868, 10.1089/end.2019.0431 · doi:10.1089/end.2019.0431
  176. Scheman, 2018, Contact allergy to propylene glycol and cross-reactions, Dermatitis, 29, 350, 10.1097/DER.0000000000000416 · doi:10.1097/der.0000000000000416

Metadata

Authors
Khan, D. A., Banerji, A., Blumenthal, K. G., Phillips, E. J., Solensky, R., White, A. A., Bernstein, J. A., Chu, D. K., Ellis, A. K., Golden, D. B. K., Greenhawt, M. J., Horner, C. C., Ledford, D., Lieberman, J. A., Oppenheimer, J., Rank, M. A., Shaker, M. S., Stukus, D. R., Wallace, D., Wang, J., Khan, D. A., Golden, D. B. K., Shaker, M., Stukus, D. R., Khan, D. A., Banerji, A., Blumenthal, K. G., Phillips, E. J., Solensky, R., White, A. A., Bernstein, J. A., Chu, D. K., Ellis, A. K., Golden, D. B. K., Greenhawt, M. J., Horner, C. C., Ledford, D., Lieberman, J. A., Oppenheimer, J., Rank, M. A., Shaker, M. S., Stukus, D. R., Wallace, D., & Wang, J.
Venue
Journal of Allergy and Clinical Immunology
Publisher
Elsevier BV
Published
2022-12
Volume
150
Issue
6
Pages
1333-1393
ISSN
0091-6749 (ISSN-L)
OpenAlex
W4296178925
Cited by
563
References
417
FWCI
48.82
Type
journal article
Language
en
Open access
bronze
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Drug allergy: A 2022 practice parameter update. https://app.cochat.ai/papers/10.1016/j.jaci.2022.08.028
The paper
Khan, D. A., Banerji, A., Blumenthal, K. G., Phillips, E. J., Solensky, R., White, A. A., Bernstein, J. A., Chu, D. K., Ellis, A. K., Golden, D. B. K., Greenhawt, M. J., Horner, C. C., Ledford, D., Lieberman, J. A., Oppenheimer, J., Rank, M. A., Shaker, M. S., Stukus, D. R., Wallace, D., . . . Wang, J. (2022). Drug allergy: A 2022 practice parameter update. Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/j.jaci.2022.08.028

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.